• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

定量纹状体多巴胺能去神经支配作为帕金森病运动结局的预测指标

Quantified Striatal Dopaminergic Denervation as Predictor for Motor Outcomes in Parkinson's Disease.

作者信息

Trinh Ilene, Muralidhar Angeni, Yang Justin, Phielipp Nicolás

机构信息

Department of Neurology School of Medicine, University of California Irvine Irvine California USA.

出版信息

Mov Disord Clin Pract. 2023 Apr 5;10(6):896-902. doi: 10.1002/mdc3.13726. eCollection 2023 Jun.

DOI:10.1002/mdc3.13726
PMID:37332639
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10272916/
Abstract

BACKGROUND

A hallmark of Parkinson's disease (PD) is progressive loss of dopamine terminals in the basal ganglia, with clinical symptoms including motor and non-motor manifestations such as bradykinesia, rigidity, and cognitive impairment. Dopamine transporter single-photon emission computed tomography (DaT-SPECT) can be used to assess dopaminergic denervation by detecting loss of striatal dopamine transporters (DaT).

OBJECTIVE

We examined DaT binding scores' (DaTbs) association with motor outcomes in PD and explored its usefulness as a predictor of disease progression. Faster dopaminergic denervation in the basal ganglia was hypothesized to have stronger correlation and predictive value for poor motor outcomes.

METHODS

Data was analyzed from the Parkinson's Progression Markers Initiative. DaTbs in the putamen and caudate nucleus were correlated with Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores for walking and balance difficulties, gait difficulties, and presence of dyskinesias. A predictive model using baseline speed of drop in DaT binding score was performed for each motor outcome.

RESULTS

All motor outcomes had mild, significantly negative correlation with DaTbs in the putamen and caudate nucleus, with similar degree of correlation per region. Speed of drop was predictive of only substantial gait difficulties when evaluated in the putamen but not the caudate.

CONCLUSIONS

These findings suggest that analyzing speed of drop in DaTbs, which occurs early in the motor phase of the disease, may be helpful for predicting clinical outcomes in PD. Longer observation of this cohort may provide further data to investigate DaTbs as a prognostic marker in PD.

摘要

背景

帕金森病(PD)的一个标志是基底神经节中多巴胺能终末的进行性丧失,其临床症状包括运动和非运动表现,如运动迟缓、僵硬和认知障碍。多巴胺转运体单光子发射计算机断层扫描(DaT-SPECT)可通过检测纹状体多巴胺转运体(DaT)的丧失来评估多巴胺能去神经支配。

目的

我们研究了DaT结合分数(DaTbs)与PD运动结局的关联,并探讨其作为疾病进展预测指标的有用性。假设基底神经节中更快的多巴胺能去神经支配与不良运动结局具有更强的相关性和预测价值。

方法

分析来自帕金森病进展标志物倡议项目的数据。壳核和尾状核中的DaTbs与运动障碍协会统一帕金森病评定量表(MDS-UPDRS)中关于步行和平衡困难、步态困难以及异动症存在情况的评分相关。针对每个运动结局,使用DaT结合分数下降的基线速度建立预测模型。

结果

所有运动结局与壳核和尾状核中的DaTbs均呈轻度、显著负相关,每个区域的相关程度相似。仅在壳核中评估时,下降速度可预测严重的步态困难,而在尾状核中则不能。

结论

这些发现表明,分析疾病运动期早期出现的DaTbs下降速度,可能有助于预测PD的临床结局。对该队列进行更长时间的观察,可能会提供更多数据,以研究DaTbs作为PD预后标志物的情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/546e/10272916/ef63c226a1c5/MDC3-10-896-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/546e/10272916/f46343fd6ef3/MDC3-10-896-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/546e/10272916/ef63c226a1c5/MDC3-10-896-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/546e/10272916/f46343fd6ef3/MDC3-10-896-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/546e/10272916/ef63c226a1c5/MDC3-10-896-g001.jpg

相似文献

1
Quantified Striatal Dopaminergic Denervation as Predictor for Motor Outcomes in Parkinson's Disease.定量纹状体多巴胺能去神经支配作为帕金森病运动结局的预测指标
Mov Disord Clin Pract. 2023 Apr 5;10(6):896-902. doi: 10.1002/mdc3.13726. eCollection 2023 Jun.
2
Associations of striatal dopamine transporter binding with motor and non-motor symptoms in early Parkinson's disease.纹状体多巴胺转运体结合与早期帕金森病运动和非运动症状的关联。
Clin Transl Sci. 2023 Jun;16(6):1021-1038. doi: 10.1111/cts.13508. Epub 2023 Mar 23.
3
Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?多巴胺转运体成像与帕金森病运动障碍的相关性:二者有多密切?
Mov Disord. 2003 Oct;18 Suppl 7:S43-51. doi: 10.1002/mds.10579.
4
Rest Tremor in Parkinson's Disease Is Associated with Ipsilateral Striatal Dopamine Transporter Binding.帕金森病中的静止性震颤与同侧纹状体多巴胺转运体结合有关。
Mov Disord. 2024 Nov;39(11):2014-2025. doi: 10.1002/mds.29997. Epub 2024 Sep 3.
5
Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease.不对称多巴胺转运体缺失影响帕金森病的认知和运动进展。
Mov Disord. 2021 Oct;36(10):2303-2313. doi: 10.1002/mds.28682. Epub 2021 Jun 14.
6
Association of Cardinal Motor Symptoms with Region-Specific Dopamine Transporter Activity in Mild to Moderate Parkinson's Disease.轻度至中度帕金森病中主要运动症状与特定区域多巴胺转运体活性的关联
Eur Neurol J. 2013;4(2):1-7.
7
Hyposmia as a marker of (non-)motor disease severity in Parkinson's disease.嗅觉障碍作为帕金森病(非)运动疾病严重程度的标志物。
J Neural Transm (Vienna). 2019 Nov;126(11):1471-1478. doi: 10.1007/s00702-019-02074-0. Epub 2019 Sep 12.
8
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.帕金森进展标志物倡议(PPMI)中无明显 LRRK2 和 GBA 突变携带者的临床和多巴胺转运体成像特征:一项横断面研究。
Lancet Neurol. 2020 Jan;19(1):71-80. doi: 10.1016/S1474-4422(19)30319-9. Epub 2019 Oct 31.
9
Relations of clinical symptoms with dopamine transporter imaging in drug-naïve Parkinson's disease.未经药物治疗的帕金森病患者的临床症状与多巴胺转运体成像的关系。
Clin Neurol Neurosurg. 2020 Sep;196:105960. doi: 10.1016/j.clineuro.2020.105960. Epub 2020 May 26.
10
Role of dopaminergic neurotransmission in pathophysiology of action tremor in Parkinson's disease.多巴胺能神经传递在帕金森病动作性震颤病理生理学中的作用。
Hell J Nucl Med. 2015 Sep-Dec;18 Suppl 1:11-6.

引用本文的文献

1
Two distinct degenerative types of nigrostriatal dopaminergic neuron in the early stage of parkinsonian disorders.帕金森病早期黑质纹状体多巴胺能神经元的两种不同退行性类型。
Clin Park Relat Disord. 2024 Feb 15;10:100242. doi: 10.1016/j.prdoa.2024.100242. eCollection 2024.

本文引用的文献

1
Factors associated with mortality in early stages of parkinsonism.帕金森病早期与死亡率相关的因素。
NPJ Parkinsons Dis. 2022 Jun 2;8(1):67. doi: 10.1038/s41531-022-00329-4.
2
Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches.帕金森病胆碱能系统改变:新兴治疗方法。
Lancet Neurol. 2022 Apr;21(4):381-392. doi: 10.1016/S1474-4422(21)00377-X. Epub 2022 Feb 4.
3
Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.帕金森病运动症状的自然史和左旋多巴的长期反应。
Brain. 2020 Aug 1;143(8):2490-2501. doi: 10.1093/brain/awaa181.
4
Long duration response in Parkinson's disease: levodopa revisited.帕金森病的长期反应:左旋多巴再探讨
Brain. 2020 Aug 1;143(8):2332-2335. doi: 10.1093/brain/awaa226.
5
Extrastriatal I-FP-CIT SPECT impairment in Parkinson's disease - the PPMI cohort.帕金森病患者纹状体外 I-FP-CIT SPECT 损伤 - PPMI 队列。
BMC Neurol. 2020 May 16;20(1):192. doi: 10.1186/s12883-020-01777-2.
6
Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures.使用基线和 1 年变化指标预测帕金森病的进展。
J Parkinsons Dis. 2019;9(4):665-679. doi: 10.3233/JPD-181518.
7
Molecular Imaging of the Dopamine Transporter.多巴胺转运体的分子影像学研究
Cells. 2019 Aug 10;8(8):872. doi: 10.3390/cells8080872.
8
Clinical implications of early caudate dysfunction in Parkinson's disease.帕金森病早期尾状核功能障碍的临床意义。
J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1098-1104. doi: 10.1136/jnnp-2018-320157. Epub 2019 May 11.
9
DaTQUANT: The Future of Diagnosing Parkinson Disease.DaTQUANT:帕金森病诊断的未来
J Nucl Med Technol. 2019 Mar;47(1):21-26. doi: 10.2967/jnmt.118.222349. Epub 2019 Jan 25.
10
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.帕金森病进展标志物计划(PPMI)——建立帕金森病生物标志物队列。
Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477. doi: 10.1002/acn3.644. eCollection 2018 Dec.